Thomas Marron MD PhD is the Director of the Early Phase Trials Unit at the Tisch Cancer Institute, and a Tenured Professor of Medicine (Heme/Onc) and a Professor of Immunology and Immunotherapy at Icahn School of Medicine at Mount Sinai. Alongside running dozens of multi-institution early-phase trials, his research focuses on development of novel immunotherapies and combinatorial therapeutic approaches, with an emphasis on translational studies in early-stage cancers. He established The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), which is a large multidisciplinary team of clinicians and scientists tasked with defining how novel therapies work through biospecimen-heavy window-of-opportunity trials. This program exploits novel immune monitoring platforms developed at Mount Sinai to characterize tissue, blood and stool from patients, enabling us to resolve the immunodynamic changes induced by standard therapies and by drugging novel immune targets. Defining the determinants of spatial makeup of the tumor immune microenvironment, and resolving the complexity within the lymphoid and myeloid lineages using a variety of single-cell transcriptomic and proteomic platforms, the aim of TARGET is to more rationally design cancer immunotherapy trials, to more rapidly advance the field and to improve patient outcomes.